38 results
PRE 14A
SHPH
Shuttle Pharmaceuticals Holdings Inc
10 Jun 24
Preliminary proxy
6:12am
Business for Mallinckrodt Pharmaceuticals Incorporated. In addition, he served as Chief Strategy and Business Development Officer from September 2019 … strategy, marketing and business development will assist our Board of Directors’ oversight role as we build and develop our Company.
Bette Jacobs, Ph.D. Dr
8-K
SHPH
Shuttle Pharmaceuticals Holdings Inc
22 May 24
Regulation FD Disclosure
4:15pm
results, strategy and plans of the Company (including certain statements which may be identified by the use of the words “plans,” “expects,” “does
8-K
SHPH
Shuttle Pharmaceuticals Holdings Inc
29 Apr 24
Other Events
10:05am
Litigation Reform Act of 1995. Forward-looking statements may relate to statements concerning future results, strategy and plans of the Company
8-K
EX-99.1
SHPH
Shuttle Pharmaceuticals Holdings Inc
23 Apr 24
Other Events
4:36pm
-looking statements may relate to statements concerning future results, strategy and plans of the Company (including certain statements which may
8-K
SHPH
Shuttle Pharmaceuticals Holdings Inc
23 Apr 24
Other Events
4:36pm
to statements concerning future results, strategy and plans of the Company (including certain statements which may be identified by the use of the words
424B3
fd6shnjispcvuo h0b3
22 Mar 24
Prospectus supplement
6:07am
8-K
jrx4uhd
13 Feb 24
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
8:00am
8-K
EX-99.1
r7y9ersm9
13 Feb 24
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
8:00am
8-K
rvr28cfvsv26 mqjr
5 Feb 24
Entry into a Material Definitive Agreement
4:25pm
8-K
7x255 hs1j
8 Jan 24
Shuttle Pharmaceuticals Receives FDA approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
9:05am
8-K
EX-99.1
4biwvip plvm5a0itl
14 Nov 23
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update
12:00am
8-K
EX-10.1
cgl2sv15
30 Oct 23
Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement
5:14pm
8-K
EX-99.1
1q70jgza2
30 Oct 23
Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement
5:14pm
8-K
r4gqnbundoxdoj1an72w
25 Sep 23
Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
9:00am
424B3
nzltxylrmukk6w51
24 Aug 23
Prospectus supplement
2:00pm
S-8
jv75 98wdct
12 Dec 22
Registration of securities for employees
4:23pm
DEF 14A
unzl 1gvwaxuap0
21 Nov 22
Definitive proxy
5:28pm